3Dahlof B,Devereux R B,Kjeldsen SE,et al.Cardiovascularmorbidity and mortality in the Losartan Intervention ForEndpoint reduction in hypertension study(LIFE):a randomizedtrial against atenolool[J].Lancet,2002,359(9311):995-1003.
7Taegtmeyer H,King LM,Jones BE. Energy substrate metabolism, myocardial ischemia, and targets for phannacotherapy. Am J Cardiol, 1998,82:54K-60K.
8Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res,2000,86: 580-588.
9Stanley WC, Lopaschuk GD, Hall JL, et al. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res, 1997,33:243-257.
10Mody FV,Singh BN, Mohiuddin IH,et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol, 1998,82:42K-49K.
